(-0.41%) 5 460.48 points
(-0.12%) 39 119 points
(-0.71%) 17 733 points
(-0.34%) $81.46
(-3.13%) $2.60
(0.01%) $2 336.90
(0.61%) $29.44
(0.28%) $1 009.00
(-0.06%) $0.933
(0.45%) $10.68
(-0.05%) $0.791
(0.86%) $85.73
@ $68.01
Išleistas: 28 birž. 2024 @ 22:51
Grąža: 0.71%
Ankstesnis signalas: birž. 28 - 21:13
Ankstesnis signalas:
Grąža: -1.33 %
Live Chart Being Loaded With Signals
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States...
Stats | |
---|---|
Šios dienos apimtis | 8.51M |
Vidutinė apimtis | 1.07M |
Rinkos kapitalizacija | 7.23B |
EPS | $-0.160 ( Q1 | 2024-05-07 ) |
Kita pelno data | ( $-0.200 ) 2024-08-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-59.04 (Sector) 42.63 (Industry) 0 |
ATR14 | $3.50 (5.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-23 | Van Nostrand Robert L | Buy | 1 567 | Common Stock |
2024-06-23 | Van Nostrand Robert L | Sell | 1 567 | Restricted Stock Units |
2024-06-23 | Salas Eduardo Rene | Buy | 1 567 | Common Stock |
2024-06-23 | Salas Eduardo Rene | Sell | 1 567 | Restricted Stock Units |
2024-06-23 | Marcus Joel S | Buy | 1 567 | Common Stock |
INSIDER POWER |
---|
6.03 |
Last 100 transactions |
Buy: 523 231 | Sell: 460 908 |
Tūris Koreliacija
Intra-Cellular Therapies Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Intra-Cellular Therapies Koreliacija - Valiuta/Žaliavos
Intra-Cellular Therapies Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $462.18M |
Bruto pelnas: | $428.43M (92.70 %) |
EPS: | $-1.460 |
FY | 2023 |
Pajamos: | $462.18M |
Bruto pelnas: | $428.43M (92.70 %) |
EPS: | $-1.460 |
FY | 2022 |
Pajamos: | $249.13M |
Bruto pelnas: | $228.69M (91.79 %) |
EPS: | $-2.72 |
FY | 2021 |
Pajamos: | $83.80M |
Bruto pelnas: | $75.77M (90.41 %) |
EPS: | $-3.50 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Intra-Cellular Therapies
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.